Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: A randomized multicenter study

Blood

Volumn 88, Issue 4, 1996, Pages 1198-1205

  Solary, Eric ^a   Witz, Brigitte ^a   Caillot, Denis ^a   Moreau, Philippe ^a   Desablens, Bernard ^a   Cahn, Jean Yves ^a   Sadoun, Alain ^a   Pignon, Bernard ^a   Berthou, Christian ^a   Maloisel, François ^a   Guyotat, Denis ^a   Casassus, Philippe ^a   Ifrah, Norbert ^a   Lamy, Yves ^a   Audhuy, Bruno ^a   Colombat, Philippe ^a   Harousseau, Jean Luc ^a  

^a HÔPITAL DU BOCAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; GLYCOPROTEIN P; MITOXANTRONE; QUINIMAX; QUININE;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; VOMITING;

EID: 9444257012     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.4.1198.bloodjournal8841198     Document Type: Article

References (45)

1. Goldie JH, Coldman AJ: Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep 67:923, 1983
2. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385, 1993
3. Marie JP, Zittoun R, Sikic BI: Multidrug resistance (mdr1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity. Blood 78:586, 1991
4. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D: Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79:473, 1992
5. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L, Ludwig H, Lechner K: MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83:708, 1991
6. Goasguen JE, Dossot JM, Fardel O, Le Mee F, Le Gall E, Leblay R, LePrise PY, Chaperon J, Fauchet R: Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: Prognostic implications. Blood 81:2394, 1993
7. Holmes J, Jacobs A, Carter G, Janowska WA, Padua RA: Multidrug resistance in haematopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukemia. Br J Haematol 72:40, 1989
8. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1697, 1981
9. Chauffert B, Martin M, Hammann A. Michel MF, Martin F: Amiodarone-induced enhancement of doxorubicin and 4′-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo. Cancer Res 46:825, 1986
10. Ford JM, Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42:155, 1990
11. Zamora JM, Pearse HL, Beck WT: Physical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 33:454, 1988
12. Genne P, Dimanche-Boitrel MT, Mauvernay RY, Gutierrez G, Duchamp O, Petit JM, Martin F, Chauffert B: Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance in vitro and in vivo. Cancer Res 52:2797, 1992
13. Pennock GD, Dalton WS, Roeske WR, Appleton CP, Mosley K, Plezia P, Miller TP, Salmon SE: Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 83:105, 1991
14. Chauffert B, Pelletier H, Corda C, Solary E, Bedenne L, Caillot D, Martin F: Potential usefulness of quinine for the circumvention of the anthracycline resistance in clinical practice. Br J Cancer 62:395, 1990
15. Solary E, Velay I, Chauffert B, Bidan JM, Caillot D, Dumas M, Guy H: Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM. Cancer 68:1714, 1991
16. Solary E, Caillot D, Chauffert B, Casasnovas RO, Dumas M, Maynadie M, Guy H: Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 10:1730, 1992
17. Benett JM, Catovsky D, Daniet MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposals for the classification of the acute leukemias. Br J Haematol 33:451, 1976
18. Solary E, Bidan JM, Calvo F, Chauffert B, Caillot D, Mugneret F, Gauville C, Tsuruo T, Carli PM, Guy H: P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukaemia and myeloma. Leukemia 5:592, 1991
19. Hiddemann W, Kreutzmann H, Sraif K, Ludwig WD, Mertelsmann R, Donhuijsen-Ant R, Lengfelder E, Arlin Z, Büchner T: High-dose cytosine arabinoside and mitoxantrone: A highly effective regimen in refractory acute myeloid leukemia. Blood 69:744, 1987
20. Bezwoda WR, Bernasconi C, Hutchinson RM, Winfield DA, de Bock R, Mandelli F: Mitoxantrone for refractory and relapsed acute leukemia. Cancer 66:418, 1990
21. O'Brien S, Kantarjian H, Estey E, Koller C, Beran M, McCredie K, Keating M: Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia. Cancer 68:691, 1991
22. Loor F, Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Emmer G: SDZ 280-446, a novel semisynthetic cyclopeptide: In vitro and in vivo circumvention of P-glycoprotein mediated tumor cell multidrug resistance. Br J Cancer 65:11, 1992
23. Sonneveld P, Nooter K: Reversal of drug resistance by cyclosporin-A in a patient with acute myelocytic leukaemia. Br J Haematol 75:208, 1990
24. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W: Phase I/II trial of cyclosporine as a chemotherapy resistance modifier in acute leukemia. J Clin Oncol 11:1652, 1993
25. Lehnert M: Reversal of P-glycoprotein-associated multidrug resistance: The challenge continues. Eur J Cancer 29:636, 1993
26. Bennis S, Ichas F, Robert J: Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line. Int J Cancer 62:283, 1995
27. Boland ME, Brennand Roper SM, Henry JA: Complications of quinine poisoning. Lancet 1:384, 1985
28. Chaudhary PM, Roninson IB: Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66:85, 1991
29. Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, Halsey J, Sikic BI: Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer 72:3502, 1993
30. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695, 1989
31. Nooter K, Oostrum R, Deurloo J: Effects of verapamil on the pharmacokinetics of daunorubicin in the rat. Cancer Chemother Pharmacol 20:176, 1987
32. Marie JP, Bastie JN, Coloma F, Faussat Suberville AM, Delmer A, Rio B, Delmas-Marsalet B, Leroux G, Casassus P, Baumelou E, Catalin J, Zittoun R: Cyclosporin A as a modifier agent in salvage treatment of acute leukemia (AL). Leukemia 7:821, 1993
33. Genne P, Duchamp P, Solary E, Magnette J, Belon JP, Chauffert B: Cinchonine per os: Efficient circumvention of P-glycoprotein - mediated multidrug resistance. Anticancer Drug Design 10:103, 1995
34. Bright JM, Buss DD: Effects of verapamil on chronic doxorubicin-induced cardiotoxicity in dogs. J Natl Cancer Inst 82:963, 1990
35. Arceci RJ: Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 81:2215, 1993
36. Haber DA: Multidrug resistance (MDR 1) in leukemia: Is it time to test? Blood 79:295, 1992
37. Holmes JA, Whittaker JA, Padua R: Effect of position 185 mutations of the MDR1 gene on drug resistance in leukemia. Leukemia 6:484, 1992
38. Bailly JD, Muller C, Jaffrezou JP, Demur C, Cassar G, Bordier C, Laurent G: Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia 9:799, 1995
39. Harker WG, Slade DL, Dalton WS, Meltzer PS, Trent JM: Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res 49:4542, 1989
40. Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP: High-dose cytosine arabinoside therapy for refractory leukemia. Blood 62:361, 1983
41. Schuurhuis GJ, Broxterman HJ, Ossenkoppele GJ, Baak JPA, Eekman CA, Kuiper CM, Feller N, van Heijningen THM, Klumper E, Pieters R, Lankelma J, Pinedo HM: Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-β-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia, Clin Cancer Res 1:81, 1995
42. Milroy R: A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. Br J Cancer 68:813, 1993
43. Millward MJ, Cantwell BMJ, Munro NC, Robinson A, Corris PA, Harris AL: Oral verapamil with chemotherapy for advanced non-small cell lung cancer: A randomized study. Br J Cancer 67:1031, 1993
44. Wishart GC, Bisett D, Paul J, Jodrell D, Harnett A, Habeshaw T, Kerr DJ, Macham MA, Soukop M, Leonard RCF, Knepil J, Kaye SB: Quinidine as a resistance modulator of epirubicin in advanced breast cancer: Mature results of a placebo-controlled randomized trial. J Clin Oncol 12:1771, 1994
45. Dalton WS, Crowley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR, Bonnet JD: A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma: A Southwest Oncology Group study. Cancer 75:815, 1995